2026-03-25 3D pentaculture model unveils malignant cell-driven macrophage polarization in high-grade serous ovarian cancer
2026-03-13 IL10RB expression in cancer cells is associated with evolutionary changes to solidify treatment resistance
2026-03-12 Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)
2026-03-10 Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort study
2026-03-09 Efficacy and immunomodulatory effect of Claudin18.2-specific IL-7/XCL1 armored CAR-T cells in digestive tract cancer: preclinical and clinical analysis
2026-03-05 Unleashing the potential of bimetallic nanobomb-mediated STING pathway to enhance bispecific T-cell engager against colorectal cancer photo-immunotherapy
2026-03-04 Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer
2026-02-27 First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial
2026-02-26 Ubenimex synergizes with the PD-L1 blockade in gastric cancer by competitively binding LAP3 with UBE3A
2026-02-26 Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial
2026-02-25 INHBA: a mitochondrial-related pan-cell death gene associated with the prognosis and immunity of OSCC
2026-02-19 Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation
2026-02-18 Identification of core cytotoxic T lymphocyte-related subtypes, establishment of a prognostic model, and analysis tumor microenvironment infiltration in HNSC
2026-02-16 LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
2026-02-13 Programmable local immunochemotherapy for triple-negative breast cancer via spatiotemporally controlled release of CpG oligodeoxynucleotides, gemcitabine, and paclitaxel
2026-02-13 DCTPP1 drives immunosuppression and poor prognosis in breast cancer by promoting M2 macrophage polarization
2026-02-12 Psychological and quality of life outcomes associated with multikinase inhibitors versus immune checkpoint inhibitors in advanced hepatocellular carcinoma
2026-02-12 The role of IL-17 in orchestrating macrophage polarization via NF-κB, mTOR/HIF-1α and pyroptosis in diabetes
2026-02-11 Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial
2026-02-11 NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss
2026-02-11 Innate lymphoid cell heterogeneity and etiology-specific reprogramming in hepatocellular carcinoma
2026-02-10 Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial
2026-02-07 Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma
2026-02-06 Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial
2026-02-05 Quantification of overall tumor burden using longitudinal magnetic resonance imaging improves response assessment in orthotopic murine hepatocellular carcinoma models
2026-02-03 Bronchial artery infusion of PD-1 inhibitors plus chemotherapy improves progression-free survival in advanced NSCLC: a prospective cohort study
2026-02-03 Integrated multi-dataset screening to predict prognosis and identify immunotherapy gene targets in hepatocellular carcinoma patients
2026-02-02 Targeting ENO1 reprograms macrophage polarization to trigger antitumor immunity and improves the therapeutic effect of radiotherapy
2026-02-02 Copy-number amplification drives IFI30 overexpression and coordinated immune activation, identifying a novel diagnostic and therapeutic target in gastric adenocarcinoma
2026-01-31 Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial
2026-01-30 Anti-TLR2 immunotherapy modulates neuron-to-oligodendrocyte propagation of α-synuclein in mouse and human models
2026-01-30 Reduced expression of BIRC2 and BIRC3 associated with longer survival in pediatric high-grade gliomas
2026-01-30 IL2Pepscan: A machine learning framework for predicting IL-2 inducing peptides and their identification across global viral proteomes
2026-01-30 Decoding the ERS–CAF immunoregulatory axis via multimodal AI and its pan-cancer prognostic and therapeutic predictive value
2026-01-29 Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial
2026-01-28 Molecular profiling of primary versus paired asynchronous metastatic clear cell renal cell carcinoma reveals heterogeneity in tumor immune microenvironment
2026-01-26 Co-delivery of chemokine CXCL9 and costimulatory ligand TNFSF9 by mesenchymal stem cells reprograms the immune microenvironment for triple-negative breast cancer
2026-01-26 Pretreatment emotional distress and peripheral biomarkers predict immune checkpoint inhibitor response in people with advanced inoperable gastroesophageal cancer
2026-01-24 TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism
2026-01-24 CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy
2026-01-24 Identification and characterization of MARCO-expressing tumor-associated macrophages in pancreatic ductal adenocarcinoma with pan-cancer relevance
2026-01-23 DTX1-mediated degradation of TUBB3 in Kupffer cells mitigates hepatocellular carcinoma progression by regulating M1/M2 polarization
2026-01-21 Antigen cross-presentation potentiating cancer vaccine adjuvant for T cell expansion and synergy with anti-PD-1
2026-01-19 In vitro experiments and bioinformatic analyses implicate KAT2A in the occurrence and development of hepatocellular carcinoma
2026-01-19 Identification of TMEM59L as a potential diagnosis, prognosis and immunotherapy biomarker for colon adenocarcinoma
2026-01-19 Radionuclide-stimulated dynamic therapy induces complementary immunogenic necroptosis and apoptosis cancer cell death pathways
2026-01-18 The tumor microenvironment in esophageal cancer and its association with clinical features and neoadjuvant treatment response
2026-01-17 Exploration of potential biomarkers in salivary duct carcinoma based on bioinformatics analysis
2026-01-17 The emerging role of SPHK1 at the immune-metabolic interface: a pan-cancer integrative analysis
2026-01-17 Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced, resectable esophageal squamous cell carcinoma: clinical study and mechanistic exploration
2026-01-16 Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial
2026-01-15 IL-15 overexpression promotes memory program and anti-tumor activity of CD64 CAR T cells in a preclinical AML model
2026-01-08 Deubiquitination-related genes define immune subtypes of colorectal cancer and are associated with prognosis and immunotherapy-related signatures
2026-01-07 Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study